Sitemap > Clinical Trials > Cancer Immunotherapy
Displaying 1 - 50 of 566 results
- A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
- Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer
- A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- A Phase II Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer
- M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
- Cetuximab in Treating Patients At High Risk of Developing Stomach Cancer
- Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
- Dendritic Cell Vaccine for High Risk Ovarian ca
- Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin
- A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
- A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
- Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
- Phase II Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma Patients at High Risk for Myelosuppression
- Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
- Phase II Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globlulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)
- Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.
- A Study of Apomab in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer
- Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
- GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
- A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
- Gleevec & Docetaxel Study in Head and Neck Squamous Cell Cancer Patients
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-Cyclophosphamide in Breast Cancer Patients
- A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma
- Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
- A Study Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer
- Bevacizumab in Treating Patients With Primary Brain Tumor, Meningioma, or Head and Neck Cancer
- Bortezomib and Rituxan Study for Patients With Waldenstrom
- Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
- Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
- Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancers (LCCC 0403)
- Interleukin-7 in Treating Patients With Refractory Metastatic Melanoma or Locally Advanced, Refractory, Metastatic Kidney Cancer
- Phase 1, Open-Label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
- Interleukin 11, Thrombocytopenia, CML, Imatinib in CML Patients
- Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
- Ibritumomab Tiuxetan for Early Stage Indolent Lymphomas
- Study of Nimotuzamab and Irintotecan in Metastatic Colorectal Cancer
- Campath in Chronic GVHD
- A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- DAHANCA 19: The Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
- A Study of Apomab in Combination With Cetuximab and Irinotecan Chemotherapy in Patients With Previously Treated Metastatic Colorectal Cancer
- Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
- Sirolimus in Treating Patients With Advanced Pancreatic Cancer
- Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
- A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
- Study of Addition of Panitumumab to Chemoradiation Therapy in Subjects With Locally Advanced Head and Neck Cancer
- Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
- Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma